0J9P.L

Incyte Corporation [0J9P.L] Stock Forecast

Q: What is Incyte Corporation stock symbol ?

Incyte Corporation is a US stock, located in Wilmington of De and trading under the symbol 0J9P.L

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

0J9P.L Stock Summary

Earnings have grown 8.87% per last year.

Earnings are expected to fall -100% next year

Profit margins (0.12%) are lower than the previous year (0.16%)

0J9P.L has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

0J9P.L

Top 10 Correlated Stocks

0J9P.L

In the News

0J9P.L Financial details

Company Rating

Strong Buy

Market Cap

12.16B

Income

597.6M

Revenue

3.7B

Book val./share

23.15

Cash/share

16.31

Dividend

Dividend %

Employees

2.52K

Optionable

Shortable

Yes

Earnings

30 Apr 2024

P/E

34.9

Forward P/E

PEG

4.7

P/S

4.09

P/B

3.01

P/C

3.22

P/FCF

25.39

Quick Ratio

3.71

Current Ratio

3.91

Debt / Equity

LT Debt / Equity

EPS (TTM)

2.67

EPS next Y

EPS next Q

EPS this Y

74.51%

EPS next Y

EPS next 5Y

EPS last 5Y

5.12%

Revenue last 5Y

11.35%

Revenue Q/Q

10.26%

EPS Q/Q

18.42%

SMA20

-7.71%

SMA50

-8.66%

SMA100

0.13%

Inst Own

Inst Trans

ROA

ROE

ROC

0.1%

Gross Margin

47%

Oper. Margin

15%

Profit Margin

12%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

50.81-75.422

52W High

-30.07%

52W Low

+4.9%

RSI

24.67

Rel Volume

0.45

Avg Volume

2.83K

Volume

1.26K

Perf Week

-4.32%

Perf Month

-11.04%

Perf Quarter

-4.29%

Perf Half Y

-8.37%

Beta

0.672

Volatility

0.9%, 2.1%

Prev Close

-0.42%

Price

52.45

Change

-0.7%

0J9P.L Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	10.04	12.23	13.55	15.29	16.53
Net income per share	2.08	-1.36	4.3	1.53	2.67
Operating cash flow per share	3.31	-0.57	3.4	4.37	2.22
Free cash flow per share	2.94	-1.43	2.58	4.02	2.01
Cash per share	9.85	8.26	10.65	14.59	16.35
Book value per share	12.09	11.97	17.1	19.68	23.21
Tangible book value per share	10.46	10.47	15.71	18.4	22.51
Share holders equity per share	12.09	11.97	17.1	19.68	23.21
Interest debt per share	0.14	0.08	0.07	0.06	0.05
Market cap	15.72B	15.95B	16.48B	17.66B	13.98B
Enterprise value	13.96B	14.5B	14.48B	14.77B	10.82B
P/E ratio	35.18	-53.95	17.37	51.85	23.4
Price to sales ratio	7.28	5.98	5.52	5.2	3.78
POCF ratio	22.12	-128.03	21.99	18.21	28.16
PFCF ratio	24.85	-51.13	28.99	19.8	31.14
P/B Ratio	6.05	6.11	4.37	4.04	2.69
PTB ratio	6.05	6.11	4.37	4.04	2.69
EV to sales	6.47	5.44	4.85	4.35	2.93
Enterprise value over EBITDA	29.31	-76.93	20.83	22.13	14.73
EV to operating cash flow	19.64	-116.38	19.32	15.23	21.79
EV to free cash flow	22.07	-46.48	25.48	16.56	24.1
Earnings yield	0.03	-0.02	0.06	0.02	0.04
Free cash flow yield	0.04	-0.02	0.03	0.05	0.03
Debt to equity	0.01	0.01	0	0	0
Debt to assets	0.01	0	0	0	0
Net debt to EBITDA	-3.7	7.7	-2.87	-4.34	-4.3
Current ratio	4.83	3.74	3.65	3.54	3.75
Interest coverage	227.33	-110.53	334.14	224.89	255.5
Income quality	1.59	0.42	0.79	2.85	0.83
Dividend Yield	0	0	0	0	0
Payout ratio	0.04	-0.08	0.03	0.08	0
Sales general and administrative to revenue	0.21	0.18	0.23	0.24	0
Research and developement to revenue	0.53	0.83	0.49	0.47	0.44
Intangibles to total assets	0.1	0.09	0.06	0.05	0.02
Capex to operating cash flow	-0.11	1.5	-0.24	-0.08	-0.1
Capex to revenue	-0.04	-0.07	-0.06	-0.02	-0.01
Capex to depreciation	-1.43	-3.62	-3.13	-1.15	-0.57
Stock based compensation to revenue	0.08	0.07	0.06	0.06	-0.16
Graham number	23.78	19.11	40.69	26.07	37.35
ROIC	0.14	-0.11	0.28	0.09	0.09
Return on tangible assets	0.15	-0.09	0.2	0.06	0.09
Graham Net	7.1	5.5	7.35	10.05	11.68
Working capital	1.97B	1.73B	2.26B	2.94B	3.41B
Tangible asset value	2.25B	2.28B	3.46B	4.09B	5.03B
Net current asset value	1.65B	1.39B	1.91B	2.58B	3.01B
Invested capital	0.01	0.01	0	0	0
Average receivables	307.85M	395.4M	549.15M	630.59M	694.22M
Average payables	93.74M	91.21M	135.44M	224.83M	193.57M
Average inventory	9.18M	13.91M	22.16M	34.95M	52.48M
Days sales outstanding	52.21	65.97	75.33	69.34	73.44
Days payables outstanding	207.3	223.03	335.34	399.86	126.94
Days of inventory on hand	28.25	37.09	54.37	60.5	72.93
Receivables turnover	6.99	5.53	4.85	5.26	4.97
Payables turnover	1.76	1.64	1.09	0.91	2.88
Inventory turnover	12.92	9.84	6.71	6.03	5
ROE	0.17	-0.11	0.25	0.08	0.12
Capex per share	-0.36	-0.86	-0.82	-0.35	-0.21

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	4.16	3.63	4.28	4.1	4.52
Net income per share	0.13	0.1	0.91	0.76	0.9
Operating cash flow per share	1.27	-0.47	1.37	0.66	0.66
Free cash flow per share	1.18	-0.59	1.34	0.61	0.65
Cash per share	14.55	13.96	15.33	15.69	16.31
Book value per share	19.63	20.02	21.24	22.01	23.15
Tangible book value per share	18.35	18.69	19.93	20.74	22.45
Share holders equity per share	19.63	20.02	21.24	22.01	23.15
Interest debt per share	0.05	0.05	0.05	0.04	0.04
Market cap	17.71B	15.98B	13.9B	12.97B	14.02B
Enterprise value	14.82B	13.2B	10.81B	9.78B	10.86B
P/E ratio	155.59	184.04	17.07	18.93	17.43
Price to sales ratio	19.11	19.76	14.56	14.11	13.83
POCF ratio	62.45	-151.29	45.34	87.75	94.89
PFCF ratio	67.51	-120.57	46.46	94.78	96.37
P/B Ratio	4.05	3.58	2.93	2.63	2.7
PTB ratio	4.05	3.58	2.93	2.63	2.7
EV to sales	15.99	16.32	11.32	10.64	10.71
Enterprise value over EBITDA	132.8	270.33	48.71	41.33	47.83
EV to operating cash flow	52.24	-124.96	35.26	66.17	73.5
EV to free cash flow	56.47	-99.59	36.12	71.48	74.64
Earnings yield	0	0	0.01	0.01	0.01
Free cash flow yield	0.01	-0.01	0.02	0.01	0.01
Debt to equity	0	0	0	0	0
Debt to assets	0	0	0	0	0
Net debt to EBITDA	-25.95	-56.97	-13.93	-13.47	-13.92
Current ratio	3.54	3.95	3.81	3.91	3.75
Interest coverage	139.97	63.12	307.79	345.64	255.26
Income quality	9.97	-4.87	1.51	0.86	0.73
Dividend Yield	0	0	0	0	0
Payout ratio	0.02	0.13	0	0.14	0
Sales general and administrative to revenue	0.08	0	0	0	0
Research and developement to revenue	0.54	0.5	0.42	0.41	0.44
Intangibles to total assets	0.05	0.05	0.05	0.04	0.02
Capex to operating cash flow	-0.07	0.25	-0.02	-0.07	-0.02
Capex to revenue	-0.02	-0.03	-0.01	-0.01	0
Capex to depreciation	-1.17	-1.4	-0.36	-0.51	-0.1
Stock based compensation to revenue	0.06	0.07	0.06	0.05	-0.25
Graham number	7.51	6.62	20.87	19.45	21.61
ROIC	0.01	0	0.03	0.03	0.03
Return on tangible assets	0.01	0	0.03	0.03	0.03
Graham Net	10.02	10.16	10.98	11.52	11.65
Working capital	2.94B	2.97B	3.15B	3.28B	3.41B
Tangible asset value	4.09B	4.17B	4.45B	4.65B	5.03B
Net current asset value	2.58B	2.64B	2.8B	2.95B	3.01B
Invested capital	0	0	0	0	0
Average receivables	631.53M	634.33M	630.89M	647.63M	700.41M
Average payables	220.36M	166.59M	105.59M	147.47M	124.51M
Average inventory	43.93M	41.44M	38.41M	46.57M	60.09M
Days sales outstanding	62.63	69.42	60.15	64.37	66.04
Days payables outstanding	346.95	70.89	168.81	165.57	114.95
Days of inventory on hand	52.5	52.08	39	67.93	66.04
Receivables turnover	1.44	1.3	1.5	1.4	1.36
Payables turnover	0.26	1.27	0.53	0.54	0.78
Inventory turnover	1.71	1.73	2.31	1.32	1.36
ROE	0.01	0	0.04	0.03	0.04
Capex per share	-0.1	-0.12	-0.03	-0.05	-0.01

0J9P.L Frequently Asked Questions

What is Incyte Corporation stock symbol ?

Incyte Corporation is a US stock , located in Wilmington of De and trading under the symbol 0J9P.L

What is Incyte Corporation stock quote today ?

Incyte Corporation stock price is $52.45 today.

Is Incyte Corporation stock public?

Yes, Incyte Corporation is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 2.83K
Market Capitalization 12.16B
Employee 2.52K
CEO Mr. Herve Hoppenot
Headquarters Wilmington,DE,US
IPO Date 2018-01-29
Website https://www.incyte.com

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.